Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02874690 · ClinicalTrials.gov registry record · Early Phase 1
Eye Tracking as a Predictor of Methylphenidate Response in Autism With ADHD
A Early Phase 1 study of Autism Spectrum Disorder and Attention Deficit Hyperactivity Disorder, sponsored by Children's Hospital Medical Center, Cincinnati.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT02874690 is a Early Phase 1 study of Autism Spectrum Disorder and Attention Deficit Hyperactivity Disorder that has completed, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 40 participants, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02874690, a Early Phase 1 study of Autism Spectrum Disorder and Attention Deficit Hyperactivity Disorder, has completed, sponsored by Children's Hospital Medical Center, Cincinnati.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall goal of this research is to use neurophysiological measures to profile strengths and deficits for Attention Deficit Hyperactivity Disorder co-morbidity in Autism Spectrum Disorder to clarify diagnosis and to predict treatment response.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Methylphenidate
Study Locations (1)
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2016-02-19 |
| Est. Completion | 2017-08-03 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02874690
The ClinicalTrials.gov registry entry for NCT02874690 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (70% lower). The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02874690 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT02874690 about?
NCT02874690 is a clinical study titled "Eye Tracking as a Predictor of Methylphenidate Response in Autism With ADHD". The overall goal of this research is to use neurophysiological measures to profile strengths and deficits for Attention Deficit Hyperactivity Disorder co-morbidity in Autism Spectrum Disorder to clarify diagnosis and to predict treatment response.
What is the current status of trial NCT02874690?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 40 participants. The study started on 2016-02-19. Estimated completion is 2017-08-03.
What conditions does trial NCT02874690 study?
This clinical trial studies the following conditions: Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder.
What interventions are being tested in trial NCT02874690?
The interventions under investigation include: Placebo (DRUG), Methylphenidate (DRUG).
Who is sponsoring clinical trial NCT02874690?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02874690 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism Spectrum Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of an 8-Week Pickleball Program for Adults With Autism: A Feasibility Trial With a Delayed-Control Design
RECRUITING · Early Phase 1
-
Effects of Drugs on Responses to Brain and Emotional Processes
COMPLETED · Early Phase 1
-
Study of Neuroimaging Biomarkers of Social Cognition Deficits in Adolescents (Age 13-17) With Autism Spectrum Disorder and Effects of Gabapentin
COMPLETED · Early Phase 1
-
Trial of Propranolol in Children and Youth With Autism Spectrum Disorder and Predictors of Response
COMPLETED · Early Phase 1
-
Cannabidiol (CBD) in Adults With ASD
RECRUITING · Phase 1
-
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.